Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
[This corrects the article DOI: 10.1371/journal.pone.0218953.].
Main Authors: | Sebastian Krug, Jan-Philipp Mordhorst, Fabian Moser, Katharina Theuerkorn, Claudia Ruffert, Maren Egidi, Anja Rinke, Thomas M Gress, Patrick Michl |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0228905 |
Similar Items
-
Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
by: Sebastian Krug, et al.
Published: (2019-01-01) -
Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
by: Thomas Gress, et al.
Published: (2012-02-01) -
Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome
by: Sebastian Krug, et al.
Published: (2019-04-01) -
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
by: Anna Kathrin Stueven, et al.
Published: (2019-06-01) -
Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
by: Kiesewetter, B., et al.
Published: (2022)